is soliqua a glp-1 it safe to use tirzepatide (glucagon-like peptide-1 receptor agonist) and (insulin glargine and lixisenatide) together in patients with type 2 diabetes and history of inadequate glycemic control? Soliqua: Dosage & Side Effects
Description
2011;34(Suppl 2):S2517
No differences in secondary endpoints (fasting insulin, pro-insulin, or C-peptide levels) were noted
The side effect profiles are very different because their mechanisms are different
According to John Halamka, MD, PhD, President of the Mayo Clinic Platform & former CIO of Harvard Universitys Beth Israel Deaconess Medical Center, the combination of Teladoc (which acquired InTouch) and Livongo address all of these areas
GLP-1 medications influence multiple metabolic pathways, including insulin secretion, glucose regulation, and energy expenditure
That means patients need sufficient protein, progressive resistance training, adequate micronutrients, and a plan that does not push them into excessive under-eating
